Graft Versus Host Disease (GVHD) - Pipeline Review, H1 2018

Publication ID:
GMD0318074

Publication Date:
March 20, 2018

Pages:
465

Publisher:
Global Markets Direct

Region:
Global [1]

$2,000.00

Publication License Type *
☐ Single User License (PDF), $2,000.00

☐ Site License (PDF), $4,000.00

☐ Global License (PDF), $6,000.00

Please choose the suitable license type from above. More details are at given under tab "Report License Types" below.
**Description:**
Graft Versus Host Disease (GVHD) - Pipeline Review, H1 2018

**Summary**

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Graft Versus Host Disease (GVHD) - Pipeline Review, H1 2018, provides an overview of the Graft Versus Host Disease (GVHD) (Immunology) pipeline landscape.

Graft-versus-host disease (GVHD) is a complication that can occur after a stem cell or bone marrow transplant in which the newly transplanted donor cells attack the transplant recipient's body. Symptoms include abdominal pain or cramps, nausea, vomiting, and diarrhea, dry or irritated eyes, jaundice, shortness of breath, vaginal dryness and weight loss. Treatment includes immunosuppressants.

**Report Highlights**

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Graft Versus Host Disease (GVHD) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Graft Versus Host Disease (GVHD) (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Graft Versus Host Disease (GVHD) (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Graft Versus Host Disease (GVHD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 8, 28, 9, 44, 9 and 2 respectively. Similarly, the Universities portfolio in Phase III, Phase I, Preclinical and Discovery stages comprises 1, 3, 12 and 1 molecules, respectively.

Graft Versus Host Disease (GVHD) (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

**Scope**
- The pipeline guide provides a snapshot of the global therapeutic landscape of Graft Versus Host Disease (GVHD) (Immunology).
- The pipeline guide reviews pipeline therapeutics for Graft Versus Host Disease (GVHD) (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Graft Versus Host Disease (GVHD) (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Graft Versus Host Disease (GVHD) (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Graft Versus Host Disease (GVHD) (Immunology)

Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Graft Versus Host Disease (GVHD) (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Graft Versus Host Disease (GVHD) (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table Of Contents:
Table of Contents
Table of Contents 2
Introduction 5
## List of Tables

<table>
<thead>
<tr>
<th>Table Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of Products under Development for Graft Versus Host Disease (GVHD), H1 2018</td>
<td>6</td>
</tr>
<tr>
<td>Number of Products under Development by Companies, H1 2018</td>
<td>7</td>
</tr>
<tr>
<td>Number of Products under Development by Universities/Institutes, H1 2018</td>
<td>23</td>
</tr>
<tr>
<td>Products under Development by Companies, H1 2018</td>
<td>34</td>
</tr>
<tr>
<td>Products under Development by Universities/Institutes, H1 2018</td>
<td>64</td>
</tr>
<tr>
<td>Number of Products by Stage and Target, H1 2018</td>
<td>35</td>
</tr>
<tr>
<td>Number of Products by Stage and Mechanism of Action, H1 2018</td>
<td>432</td>
</tr>
<tr>
<td>Number of Products by Stage and Route of Administration, H1 2018</td>
<td>437</td>
</tr>
<tr>
<td>Number of Products by Stage and Molecule Type, H1 2018</td>
<td>438</td>
</tr>
<tr>
<td>Graft Versus Host Disease (GVHD) - Pipeline by AbbVie Inc, H1 2018</td>
<td>438</td>
</tr>
<tr>
<td>Graft Versus Host Disease (GVHD) - Pipeline by AbGenomics International Inc, H1 2018</td>
<td>438</td>
</tr>
<tr>
<td>Graft Versus Host Disease (GVHD) - Pipeline by Amgen Inc, H1 2018</td>
<td>438</td>
</tr>
<tr>
<td>Graft Versus Host Disease (GVHD) - Pipeline by Amunix Operating Inc, H1 2018</td>
<td>438</td>
</tr>
<tr>
<td>Graft Versus Host Disease (GVHD) - Pipeline by AnaptysBio Inc, H1 2018</td>
<td>438</td>
</tr>
<tr>
<td>Graft Versus Host Disease (GVHD) - Pipeline by apceth Biopharma GmbH, H1 2018</td>
<td>438</td>
</tr>
<tr>
<td>Graft Versus Host Disease (GVHD) - Pipeline by Aptevo Therapeutics Inc, H1 2018</td>
<td>438</td>
</tr>
<tr>
<td>Graft Versus Host Disease (GVHD) - Pipeline by arGEN-X BV, H1 2018</td>
<td>438</td>
</tr>
<tr>
<td>Graft Versus Host Disease (GVHD) - Pipeline by Athysys Inc, H1 2018</td>
<td>438</td>
</tr>
<tr>
<td>Graft Versus Host Disease (GVHD) - Pipeline by Bellicum Pharmaceuticals Inc, H1 2018</td>
<td>438</td>
</tr>
<tr>
<td>Graft Versus Host Disease (GVHD) - Pipeline by Biogen Inc, H1 2018</td>
<td>438</td>
</tr>
<tr>
<td>Graft Versus Host Disease (GVHD) - Pipeline by Bristol-Myers Squibb Co, H1 2018</td>
<td>438</td>
</tr>
<tr>
<td>Graft Versus Host Disease (GVHD) - Pipeline by Capricor Therapeutics Inc, H1 2018</td>
<td>438</td>
</tr>
<tr>
<td>Graft Versus Host Disease (GVHD) - Pipeline by Cell2B Advanced Therapeutics SA, H1 2018</td>
<td>438</td>
</tr>
<tr>
<td>Graft Versus Host Disease (GVHD) - Pipeline by Cellect Biotechnology Ltd, H1 2018</td>
<td>438</td>
</tr>
<tr>
<td>Graft Versus Host Disease (GVHD) - Pipeline by CSL Ltd, H1 2018</td>
<td>438</td>
</tr>
<tr>
<td>Graft Versus Host Disease (GVHD) - Pipeline by Cynata Therapeutics Ltd, H1 2018</td>
<td>438</td>
</tr>
<tr>
<td>Graft Versus Host Disease (GVHD) - Pipeline by Cytodyn Inc, H1 2018</td>
<td>438</td>
</tr>
<tr>
<td>Graft Versus Host Disease (GVHD) - Pipeline by Elsalys Biotech SAS, H1 2018</td>
<td>438</td>
</tr>
</tbody>
</table>
Graft Versus Host Disease (GVHD) - Pipeline by Enlivex Therapeutics Ltd, H1 2018
Graft Versus Host Disease (GVHD) - Pipeline by Escape Therapeutics Inc, H1 2018
Graft Versus Host Disease (GVHD) - Pipeline by F. Hoffmann-La Roche Ltd, H1 2018
Graft Versus Host Disease (GVHD) - Pipeline by Fate Therapeutics Inc, H1 2018
Graft Versus Host Disease (GVHD) - Pipeline by Generon (Shanghai) Corp Ltd, H1 2018
Graft Versus Host Disease (GVHD) - Pipeline by Gilead Sciences Inc, H1 2018
Graft Versus Host Disease (GVHD) - Pipeline by GlaxoSmithKline Plc, H1 2018
Graft Versus Host Disease (GVHD) - Pipeline by Incyte Corp, H1 2018
Graft Versus Host Disease (GVHD) - Pipeline by Inspyr Therapeutics Inc, H1 2018
Graft Versus Host Disease (GVHD) - Pipeline by Jazz Pharmaceuticals Plc, H1 2018
Graft Versus Host Disease (GVHD) - Pipeline by Johnson & Johnson, H1 2018
Graft Versus Host Disease (GVHD) - Pipeline by Kadmon Corp LLC, H1 2018
Graft Versus Host Disease (GVHD) - Pipeline by Kamada Ltd, H1 2018
Graft Versus Host Disease (GVHD) - Pipeline by Kiadis Pharma NV, H1 2018
Graft Versus Host Disease (GVHD) - Pipeline by Kymab Ltd, H1 2018
Graft Versus Host Disease (GVHD) - Pipeline by LG Chem Ltd, H1 2018
Graft Versus Host Disease (GVHD) - Pipeline by MaaT Pharma, H1 2018
Graft Versus Host Disease (GVHD) - Pipeline by MacroGenics Inc, H1 2018
Graft Versus Host Disease (GVHD) - Pipeline by MallInckrodt Plc, H1 2018
Graft Versus Host Disease (GVHD) - Pipeline by Mesoblast Ltd, H1 2018
Graft Versus Host Disease (GVHD) - Pipeline by Millennium Pharmaceuticals Inc, H1 2018
Graft Versus Host Disease (GVHD) - Pipeline by Novartis AG, H1 2018
Graft Versus Host Disease (GVHD) - Pipeline by OncoImmune Inc, H1 2018
Graft Versus Host Disease (GVHD) - Pipeline by Pfizer Inc, H1 2018
Graft Versus Host Disease (GVHD) - Pipeline by Pharmicell Co Ltd, H1 2018
Graft Versus Host Disease (GVHD) - Pipeline by Pluristem Therapeutics Inc, H1 2018
Graft Versus Host Disease (GVHD) - Pipeline by REGiMMUNE Corp, H1 2018
Graft Versus Host Disease (GVHD) - Pipeline by Sanofi, H1 2018
Graft Versus Host Disease (GVHD) - Pipeline by Sarepta Therapeutics Inc, H1 2018
Graft Versus Host Disease (GVHD) - Pipeline by Seattle Genetics Inc, H1 2018
Graft Versus Host Disease (GVHD) - Pipeline by Seres Therapeutics Inc, H1 2018
Graft Versus Host Disease (GVHD) - Pipeline by Sigmoid Pharma Ltd, H1 2018
Graft Versus Host Disease (GVHD) - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2018
Graft Versus Host Disease (GVHD) - Pipeline by Targazyme Inc, H1 2018
Graft Versus Host Disease (GVHD) - Pipeline by TC BioPharm Ltd, H1 2018
Graft Versus Host Disease (GVHD) - Pipeline by TxCel SA, H1 2018
Graft Versus Host Disease (GVHD) - Pipeline by United BioPharma Inc, H1 2018
Graft Versus Host Disease (GVHD) - Pipeline by Vault Pharma Inc, H1 2018
Graft Versus Host Disease (GVHD) - Pipeline by VBI Vaccines Inc, H1 2018
Graft Versus Host Disease (GVHD) - Pipeline by Xenikos BV, H1 2018
List of Figures

Number of Products under Development for Graft Versus Host Disease (GVHD), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Top 10 Molecule Types, H1 2018
Number of Products by Stage and Top 10 Molecule Types, H1 2018

**Companies Mentioned:**

AbbVie Inc
AbGenomics International Inc
Amgen Inc
Amunix Operating Inc
AnaptysBio Inc
apceth Biopharma GmbH
Aptevo Therapeutics Inc
arGEN-X BV
Athersys Inc
Bellicum Pharmaceuticals Inc
Biogen Inc
Bristol-Myers Squibb Co
Capricor Therapeutics Inc
Cell2B Advanced Therapeutics SA
Cellect Biotechnology Ltd
CSL Ltd
Cynata Therapeutics Ltd
Cytodyn Inc
Elsalys Biotech SAS
Enlivex Therapeutics Ltd
Escape Therapeutics Inc
F. Hoffmann-La Roche Ltd
Fate Therapeutics Inc
Generon (Shanghai) Corp Ltd
Gilead Sciences Inc
GlaxoSmithKline Plc
Incyte Corp
Inspyr Therapeutics Inc
Jazz Pharmaceuticals Plc
Johnson & Johnson
Kadmon Corp LLC
Kamada Ltd
Kiadis Pharma NV
Kymab Ltd
LG Chem Ltd
MaaT Pharma
MacroGenics Inc
Mallinckrodt Plc
Mesoblast Ltd
Millennium Pharmaceuticals Inc
Novartis AG
OncoImmune Inc
Pfizer Inc
Pharmicell Co Ltd
Pluristem Therapeutics Inc
REGIMMUNE Corp
Sanofi
Sarepta Therapeutics Inc
Seattle Genetics Inc
Seres Therapeutics Inc
Sigmoid Pharma Ltd
Takeda Pharmaceutical Co Ltd
Targazyme Inc
TC BioPharm Ltd
TxCell SA
United BioPharma Inc
Vault Pharma Inc
VBI Vaccines Inc
Xenikos BV
License Types:

Single User License (PDF)

- This license allows for use of a publication by one person.
- This person may print out a single copy of the publication.
- This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- This person cannot share the publication (or any information contained therein) with any other person or persons.
- Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

Site License (PDF)*

- This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
- These users may print out a single copy of the publication.
- These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
- Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

Global License (PDF)*

- This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
- Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
- These employees of purchasing organization can include information given in the publication in
presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.